Hims & Hers stock plummeted 26% after the FDA resolved the semaglutide shortage, impacting their compounded weight loss drug business. Hims & Hers faces a significant revenue risk, as the FDA’s ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Roughly a year after receiving an FDA reprimand at its manufacturing plant in Michigan, Indian drugmaker Piramal Pharma has ...
Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females also tend to experience more weight loss on Ozempic, as well as a larger ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...